NSW Health invite you to participate in the first NSW based patient - centered clinical study to trial TGA approved cannabis medicine (EPIDYOLEX) for people with rare DEE *.
* DEE is a rare form of epilepsy characterized by recurrent, unprovoked seizures.
Connect with our senior clinicians and NSW health to schedule an appointment.
To evaluate the safety and effectiveness of TGA approved cannabis (Epidyolex) in reducing seizures and quality of life.
10 months
Cannabis medicine (Epidyolex) has some evidence of efficacy when used as an adjuvant to other anti epileptic therapy. Most published clinical and pre-clinical data on efficacy in epilepsy is with Cannabis medicine in children and adults with rare epilepsy such as DEE.
* Patients will need to pass a 10 min screening session
We have limited spots. The recruitment closing date is approaching fast. Don’t miss out!
DaysDays
HrsHours
MinsMinutes
SecsSeconds
This project is approved by the Hunter New England Local Health District, NSW Health (2024/ETH00559). Your information will not be shared with third parties, including the study sites, clinical research organizations, the Eligibility Review Board, and regulatory or public health agencies. HAIKDA research is a collabora